Case Report

Nonhepatic Hyperammonemia With Septic Shock: Case and Review of Literature

Nishil Dalsania, MD¹, Suhali Kundu, MD¹, Ravi Karan Patti, MBBS¹, Navjot Somal, MBBS¹, and Yizhak Kupfer, MD¹

Abstract
Elevated ammonia levels lead to cerebral edema, encephalopathy, seizures, coma, and death. Hyperammonemia is primarily associated with liver disease; however, there are rare cases without liver disease. Noncirrhotic hyperammonemia is primarily due to increased production and/or decreased elimination of ammonia. We present a rare case of a 35-year-old female with severe acute noncirrhotic hyperammonemia associated with gram-negative septic shock and a suspected undiagnosed partial urea cycle enzyme deficiency. She had elevated blood and urine amino acid levels speculated to be due to an underlying urea cycle defect, which was unmasked in the setting of septic shock with urea splitting bacteria leading to severely elevated ammonia levels. Ammonia levels were rapidly corrected with hemodialysis, as other conventional treatments failed. We highlight the importance of considering noncirrhotic causes of hyperammonemia in patients with elevated ammonia levels and intact liver function. Prompt treatment should begin with reducing the catabolic state, nitrogen scavenging, replacing urea cycle substrates, decreasing intestinal absorption, and augmented removal of ammonia with renal replacement therapy.

Keywords
hyperammonemia, septic shock, pulmonary critical care, urea cycle disorder, encephalopathy, cirrhosis, neurology, nephrology

Introduction

Hyperammonemia is generally associated with severe liver disease, and 50% to 70% of cirrhotic patients develop encephalopathy.¹ A minority of cases develop without severe liver disease; in these cases of elevated ammonia (NH₃) not due to cirrhosis, etiologies such as urea cycle enzyme deficiencies, drugs, infections, ureterosigmoidostomy, increased cellular catabolism, and chemotherapy should be considered.¹ Ammonia is toxic to cells and converted to nontoxic metabolites, such as urea or glutamine. Urea is produced in periportal hepatocytes after uptake from the portal blood and subsequently excreted via the kidneys. If detoxification of ammonia does not occur, it is trapped in perivenous hepatocytes and converted to glutamine by glutamine synthetase.²,³

Noncirrhotic hyperammonemia is due to the inability of the liver to meet the metabolic demands during excess ammonia production and/or portal circulation bypass of the toxic metabolites directly into systemic circulation.¹ The exact pathogenesis of hyperammonemnemic encephalopathy is multifactorial and incompletely understood, but is believed to occur since ammonia can penetrate the blood-brain barrier by passive diffusion or mediated transport leading to neurotransmitter synthesis disruption.⁴,⁵ Ammonia directly affects neuronal electric activity by inhibiting the generation of both excitatory and inhibitory postsynaptic potentials.⁵,⁶ Astrocytes are the only brain cells that can metabolize ammonia due to the presence of glutamine synthetase, which generates glutamine from glutamate and ammonia. Glutamine plays a crucial role in neurotoxicity of ammonia on the brain; astrocytes metabolize glutamine in the mitochondria leading to the production of ammonia and reactive oxygen species (ROS). Under normal physiologic conditions, there are low concentrations of glutamine within the astrocytes; however, when there is elevate systemic ammonia levels, there is increased glutamine hydrolysis and ammonia production within the mitochondria leading to increased ROS. The ROS perpetuates mitochondrial dysfunction and triggers

¹Maimonides Medical Center, Brooklyn, NY, USA

Received February 13, 2022. Revised April 7, 2022. Accepted May 1, 2022.

Corresponding Author:
Nishil Dalsania, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA.
Email: ndalsania@maimonidesmed.org

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
inflammatory cascades. Furthermore, glutamine affects the osmoregulatory function of astrocytes; elevated ammonia and glutamine levels causes movement of water into the astrocytes, leading to an osmotic imbalance, swelling, and cerebral edema. Glutamine and ammonia leading to astrocyte swelling and generation of ROS is thought to trigger inflammatory cascades, apoptosis, and metabolic pathways that lead to elevated lactate, cerebral edema, and loss of cerebral auto regulation.

Although hyperammonemia-related encephalopathy is mainly associated with cirrhotic dysfunction in majority of the cases, it is important to consider noncirrhotic causes of elevated ammonia. We present a case of severe acute noncirrhotic hyperammonemia and related encephalopathy associated with gram-negative septic shock in the setting of a prior undiagnosed underlying urea cycle enzyme deficiency.

Case
A 35-year-old female with past medical history acute lymphocytic leukemia (in remission since 1997), diabetes melittus, bipolar disorder, recurrent urinary tract infections, and obesity status post gastric bypass surgery, who presented with altered mental status for 1 day. Per mother, there is no significant family history, and she had been bedbound for 3 months, withdrawn, with decreased appetite and poor nutrition. In the emergency department she was afebrile, tachycardic to 150 bpm, tachypneic to 30-40 bpm, and hypotensive to 72/52 mm Hg. On physical examination, she was found to have severe cachexia, mottled bilateral upper extremities, necrotic sacral decubitus ulcer, sluggish bilateral pupils with fixed + dilated pupils, positive Chvostek’s, and Romberg’s sign. Patient was noted to have episodes of rhythmic jerking movements of her head, jaw, and tongue with right downward gaze, which subsided with IV benzodiazepines and levetiracetam. She underwent a second continuous video EEG, which showed the development of near-continuous approximately 0.5 to 1.5 Hz left hemispheric posteriorly predominant blunted lateralized periodic discharges, intermittently occurring as posteriorly maximal generalized periodic discharges more prominent over the left hemisphere with fluctuation in amplitude and sharp contour but no evolution over time. Findings were concerning for focal epilepsy, though there was no electrographic seizures, and evidence of severe diffuse cerebral dysfunction, typically seen in the context of toxic-metabolic encephalopathies and/or due to a medication effect. Brain magnetic resonance imaging (MRI) showed diffuse gyriform restricted diffusion throughout the cerebral hemispheres and insula bilaterally, which is seen typically with elevated ammonia levels (Figure 1). Given elevated ammonia levels of 551 µmol/L refractory to medical therapy, she was placed on continuous veno-venous hemodialysis (CVVHD). Urine and plasma amino acids were abnormal with severely elevated glutamine (plasma level 1926.8 µM 205-756 µM; urine level 1575 nmol/mg Cr 93-686 nmol/mg), glutamic acid (plasma level 147.3 µM 10-131 µM; urine level 89 nmol/mg Cr <34 nmol/mg), asparagine (plasma level 171.7 µM 35-74 µM), urinary ornithine (plasma level 140.3 µM 48-195 µM), and citrulline (plasma level 37.5 µM 12-55 µM; urine level 3 nmol/mg Cr <12 nmol/mg) suggestive for a possible underlying urea cycle enzyme deficiency. Zinc levels were not measured since she received zinc supplementation on admission to the intensive care unit (ICU). Carnitine levels were normal; however, acylcarnitine/carnitine ratio levels were elevated.

The patient was removed from CVVHD after maximal decrease in ammonia level to 55 µmol/L. On day 22, she had
a tracheostomy placed and was able to track motion with her
eyes with minimal responsiveness to painful stimuli.

**Discussion**

Hyperammonemia is a metabolic disturbance typically due
to intrinsic liver disease with elevated ammonia levels in the
blood. Extreme elevations of blood ammonia levels can be
life-threatening and cause severe neurologic dysfunction.
Treatment should be rapidly instated and ammonia levels
should be quickly reduced. Elevated ammonia levels that are
not related to intrinsic liver disease may be a result of
increased ammonia production or decreased elimination of
ammonia.9

Increased ammonia production may be related to infec-
tions by urease-producing bacteria, hematological-oncologi-
cal disorders, organ transplant, and increased protein
catabolism. We will focus on increased production of ammo-
nia due to infections by urease-producing bacteria, which
include Proteus mirabilis, Klebsiella sp., E coli, Morganella
morganii, Providencia sp., Pseudomonas sp., Anaerobic spe-
cies, Staphylococcus sp., Helicobacter sp., and Mycobacterium sp.5,10 These bacteria hydrolyze urea, leading
to the increased production of NH3. In uropathogenic
strains, the urine becomes alkalinized, thus allowing for
increasing concentrations of ammonia and ammonium by up
to 50% compared with approximately 5% to 10% in neutral
pH.10 Ammonia is electrically neutral and lipid soluble.

Therefore, increased urinary ammonia concentration pro-
duces a gradient leading to diffusion of NH3 into urothelial
cells. Within the urothelial cells, it is converted to the less
permeable ammonium (NH4+) in the setting of a neutral pH
7.4, preventing diffusion back into the urine, this is known as
“diffusion trapping.”11,12 Trapped ammonium enters the sys-
temic circulation via the venous drainage of the bladder
escaping detoxification by the liver and contributing to
hyperammonia and hyperammonemic encephalopathy.11-13

Decreased elimination may be related to ureterosigmoid-
ostomy, portosystemic shunts, and drug-induced and
inborn errors of metabolism (eg. urea cycle disorders or
mitochondrial cycle disorders).1,9 We will focus on
decreased elimination of ammonia related to urea cycle dis-
orders (UCDs). Figure 2 highlights the role of urea cycle in
the excretion of ammonia,14 deficiencies in any of the
enzymes will lead to disruption of urea synthesis, leading to
accumulation of ammonia and other metabolites depending
on where the pathway is blocked.15 A portion of the urea
cycle takes place in the mitochondria; the conversion of
carbamoyl phosphate to citrulline with ornithine transcar-
bamylyase (OTC) and ornithine. Therefore, deficiency of
OTC would potentiate hyperammonemia, and any other
disturbances within the mitochondria could lead to dys-
function in cellular energy metabolism and ammonium
accumulation.16 In patients with partial deficiency, enzyme
activities may vary, and symptoms may occur during times
of physiological stress such as infective illness, childbirth,
Ornithine transcarbamylase (ODC) deficiency is the most common of the urea cycle disorders, it has an X-linked inheritance pattern and can have extremely varied expression from neonates to adults. Males are primarily affected and typically present in the neonatal period. However, there have been case reports in older children and adults including homozygous males and heterozygous females. Another UCD with similar biochemical markers as OTC deficiency is carbamoyl phosphate synthetase-1 (CPS-1) deficiency. It is rare, with an autosomal recessive inheritance pattern and 2 phenotypes: neonates or late form. CPS-1 may lead to lethal hyperammonemia with complete deficiency; however, with partial deficiency or late form presentation, patients may have recurrent bouts of hyperammonemia associated with physiological stresses.

OTC is a zinc enzyme, its activity decreases if there is any form zinc deficiency, which occurs in patients with chronic liver disease, with malabsorption disease such as inflammatory bowel disease (IBD) or patients with gastric bypass surgeries like our patient. Zinc deficiency thereby reduces hepatic capacity to metabolize ammonia; in healthy patients, the glutamine-synthesizing system in skeletal muscles compensates for the decrease in ammonia metabolism by the liver and hyperammonemia does not develop.

Clinical features of hyperammonemia vary and include symptoms caused by ammonia toxicity to the brain. They include personality changes, lethargy, vomiting, irritability, confusion, and in severe cases seizures, stupor, coma, and death. Workup for hyperammonemia includes measuring blood levels of ammonia, with levels >150 µmol/L patients will typically be encephalopathic. In isolated hyperammonemia with no liver dysfunction, acid-base status, serum bicarbonate, sodium, chloride, and urinary ketones should be evaluated. Respiratory alkalosis in the absence of metabolic acidosis may be an indication of urea cycle disorder. As a workup of UCD, both plasma and urine amino acids should be measured. Neuroimaging demonstrates characteristic changes of hyperammonemia encephalopathy, diffusion restriction seen with diffusion weight imaging (DWI) on MRI are predominantly in the cortex—mainly the insular cortex and cingulate gyrus and are diffuse, symmetrical, and
have corresponding fluid attenuated inversion recovery (FLAIR) hyperintensities (Figures 1 and 3).\textsuperscript{22-24} The biochemical abnormalities seen with OTC deficiency and CPS-1 deficiency include hyperammonemia, elevated levels of glutamine, alanine, and asparagine, which serve as storage forms of waste nitrogen, and normal or decreased levels of citrulline. To differentiate between the 2 deficiencies, urine orotic acid is measured and elevated in OTC deficiency.\textsuperscript{1,20}

Our patient had culture positive \textit{E coli} in the urine and respiratory cultures, \textit{M morganii} in the blood, and \textit{P mirabilis} in the stool. These bacteria are all urease-producing bacteria, leading to diffusion trapping and catastrophic elevation of plasma ammonia levels sufficient to oversaturate hepatic excretory pathways. Her MRI brain findings were characteristic of hyperammonemia. In addition, she was found to have respiratory alkalosis and elevated amino acid levels in the blood and urine: elevations of glutamine, glycine, alanine, and proline suggestive of a urea cycle disorder, with possibly an OTC or CPS-1 deficiency leading to decreased metabolism of ammonia. Concomitantly, our patient may have also had an acquired zinc deficiency from her gastric bypass surgery, which would potentiate impairment of ammonia metabolism. However, our patient was receiving oral zinc supplementation in the intensive care unit, which likely prevented her ammonia levels from rising further.

Treatment was started with antibiotics specific for these infections to help mitigate the burden of ammonia in the body and help restore the initial function of the kidneys and nervous system. Antibiotics would decrease bacterial proliferation and lower urease concentrations, which would subsequently lead to less hydrolysis of urea into ammonia. Further treatment for our patient included lactulose, rifaximin, l-carnitine, along with high-concentration dextrose intravenous fluids, all of which did not lower the ammonia levels sufficiently to nontoxic concentration and she required CVVHD to further facilitate ammonia elimination.

A targeted diagnostic evaluation for urea cycle enzyme deficiency was not done for our patient prior to her passing. However, we can speculate that she had a partial underlying urea cycle deficiency likely, a heterozygous carrier for OTC or carrier of CPS-1 deficiency unmasked by septic shock caused by urea splitting gram-negative bacteria causing such a profound elevation of ammonia.

Early intervention is crucial in severe elevations of ammonia, with the goal to rapidly reduce production of nitrogen waste and blood ammonia levels.\textsuperscript{25} Initial therapy should begin with reducing the catabolic state, nitrogen scavenging, replacing urea cycle substrates, and decreasing intestinal absorption; subsequent use of renal replacement therapy is suggested. Restriction of protein intake, high-dose intravenous glucose/fat, and low-dose continuous insulin infusion are needed to reduce the catabolic state. Nitrogen scavenger therapy with sodium phenylacetate and sodium benzoate, sodium phenylbutyrate, or glycerol phenylbutyrate assist by diverting nitrogen from the urea cycle to alternative routes of excretion. Lactulose and rifaximin are conventionally used

\textbf{Figure 3.} T2-Fluid Attenuated Inversion Recovery (FLAIR) images with extensive bilateral hyperintensity in the cortex, including cingulate and insular cortices (yellow arrows) typically seen with elevate ammonia levels.
to decrease intestinal absorption of ammonia. L-carnitine is frequently used in the setting of hepatic encephalopathy. L-carnitine can augment ureagenesis, along with further decreasing levels through fatty acid oxidation, and stimulation of protein membrane phospholipid synthesis preventing excessive neuronal cell death. Renal replacement therapy (RRT) for the management of hyperammonemia has been instituted with intent to quickly reduce ammonia levels by reducing the catabolic state, nitrogen scavenging, replacing urea cycle substrates, decreasing intestinal absorption, and removal with RRT.

Conclusion

Hyperammonemia is most often related to liver cirrhosis. However, noncirrhotic hyperammonemia should be included in the differential diagnosis of patients presenting with encephalopathy, intact synthetic liver function, and elevated ammonia levels. Our case highlights that sepsis with urea cycle disorders and lead to profound hyperammonemic encephalopathy and death. Prompt intervention should be instituted with intent to quickly reduce ammonia levels by reducing the catabolic state, nitrogen scavenging, replacing urea cycle substrates, decreasing intestinal absorption, and removal with RRT.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

ORCID iD

Nishil Dalsania https://orcid.org/0000-0003-1537-6257

References

1. Laish I, Ben Ari Z. Noncirrhotic hyperammonaemic encephalopathy. Liver Int. 2011;31:1259-1270.
2. Treem WR. Inherited and acquired syndromes of hyperammonemia and encephalopathy in children. Semin Liver Dis. 1994;14:236-258.
3. Olde Damink SW, Jalan R, Depong CH. Interorgan ammonia trafficking in liver disease. Metab Brain Dis. 2009;24:169-181.
4. Upadhyay R, Bleck TP, Busl KM. Hyperammonemia: what urea-lly need to know: case report of severe noncirrhotic hyperammonemic encephalopathy and review of the literature. Case Rep. Med. 2016;2016:8512721.
5. Ott P, Vilstrup H. Cerebral effects of ammonia in liver disease: current hypotheses. Metab Brain Dis. 2014;29(4):901-911.
6. Raabe W. Ammonium ions abolish excitatory synaptic transmission between cerebellar neurons in primary dissociated tissue culture. J Neurophysiol. 1992;68(1):93-99.
7. Cichoń-Lach H, Michalak C. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy. World J Gastroenterol. 2013;19(1):26-34.
8. Hertz L, Kala G. Energy metabolism in brain cells: effects of elevated ammonia concentrations. Metab Brain Dis. 2007;22(3-4):199-218.
9. Kumar S, Asrani SK. Non-cirrhotic hyperammonemia—when high ammonia is not always from cirrhosis. Curr Hepatol Rep. 2015;14:25-31.
10. Konieczna I, Zarnowiec P, Kwinkowski M, et al. Bacterial urea and its role in long-lasting human diseases. Curr Protein Pept Sci. 2012;13:789-806.
11. Cheang HK, Rangecroft L, Plant L, et al. Hyperammonemia due to Klebsiella infection in a neuropathic bladder. Pediatr Nephrol. 1998;12:658-659.
12. Samtoy B, DeBeukelaer MM. Ammonia encephalopathy secondary to urinary tract infection with Proteus mirabilis. Pediatrics. 1980;65:294-297.
13. Murray T, Comeau LL. Hyperammonemic coma caused by Providencia rettgeri infection in a child with prune belly syndrome. Pediatr Crit Care Med. 2002;2(2):178-180.
14. Machado MC, Pinheiro da Silva F. Hyperammonemia due to urea cycle disorders: a potentially fatal condition in the intensive care setting. J Intensive Care. 2014;2(1):22.
15. Hawkes ND, Thomas GA, Jurewicz A, et al. Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J. 2001;77:717-722.
16. Arn PH, Hauser ER, Thomas GH, et al. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus: a cause of post-partum coma. N Engl J Med. 1990;322:1652-1655.
17. Rowe PC, Newman SL, Brusilow SW. Natural history of symptomatic partial ornithine transcarbamylase deficiency. N Engl J Med. 1986;314:541-547.
18. Ah Mew N, Simpson KL, Gropman AL, et al. Urea cycle disorders overview. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. 1993.
19. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005;21:S1-S8.
20. Hoffman GF, Nyhan WL, Zschocke J, et al. Inherited Metabolic Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
21. de Havenon A, French K, Ansari S. Extensive cortical diffusion restriction in a 50-year-old female with hyperammonemic encephalopathy and status epilepticus. Case Rep Neurol Med. 2014;2014:257094.
22. U-King-Im JM, Yu E, Bartlett E, Soobrah R, Kucharczyk W. Acute hyperammonemic encephalopathy in adults: imaging findings. AJNR Am J Neuroradiol. 2011;32(2):413-418.
23. Rosario M, McMahon K, Finelli PF. Diffusion-weighted imaging in acute hyperammonemic encephalopathy. Neurohospitalist. 2013;3(3):125-130.
24. Gupta S, Fenves AZ, Hootkins R. The role of RRT in hyperammonemic patients. Clin J Am Soc Nephrol. 2016;11(10):1872-1878.
25. Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2019;1:CD011451.
26. Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16:471-482.
27. Collen JF, Das NP, Koff JM, NeffRT, Abbott KC. Hemodialysis for hyperammonemia associated with ornithine transcarbamylase deficiency. Appl Clin Genet. 2008;1:1-5.
28. Felipo V, Butterworth RF. Mitochondrial dysfunction in acute hyperammonemia. Neurochem Int. 2002;40(6):487-491.
29. Redant S, Empain A, Mugisha A, et al. Management of late onset urea cycle disorders—a remaining challenge for the intensivist? Ann Intensive Care. 2021;11:2.
30. Wilkinson DJ, Smeeton NJ, Watt PW. Ammonia metabolism, the brain and fatigue; revisiting the link. Prog Neurobiol. 2010;91(3):200-219.